This company has been marked as potentially delisted and may not be actively trading. Rain Oncology (RAIN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesInsider TradesTrendsBuy This Stock RAIN vs. YOTA, WAVS, SHMD, GDST, AOGO, ELPW, INTE, DIST, MCAE, and BRACShould you be buying Rain Oncology stock or one of its competitors? The main competitors of Rain Oncology include Yotta Acquisition (YOTA), Western Acquisition Ventures (WAVS), SCHMID Group (SHMD), Goldenstone Acquisition (GDST), Arogo Capital Acquisition (AOGO), Elong Power (ELPW), Integral Acquisition Co. 1 (INTE), Distoken Acquisition (DIST), Mountain Crest Acquisition Corp. III (MCAE), and Broad Capital Acquisition (BRAC). These companies are all part of the "holding & other investment offices" industry. Rain Oncology vs. Yotta Acquisition Western Acquisition Ventures SCHMID Group Goldenstone Acquisition Arogo Capital Acquisition Elong Power Integral Acquisition Co. 1 Distoken Acquisition Mountain Crest Acquisition Corp. III Broad Capital Acquisition Yotta Acquisition (NASDAQ:YOTA) and Rain Oncology (NASDAQ:RAIN) are both small-cap companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, community ranking, media sentiment, risk and dividends. Which has more risk & volatility, YOTA or RAIN? Yotta Acquisition has a beta of 0.05, suggesting that its stock price is 95% less volatile than the S&P 500. Comparatively, Rain Oncology has a beta of -0.11, suggesting that its stock price is 111% less volatile than the S&P 500. Which has preferable earnings & valuation, YOTA or RAIN? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioYotta AcquisitionN/AN/AN/AN/AN/ARain OncologyN/AN/A$3.10MN/AN/A Does the media refer more to YOTA or RAIN? In the previous week, Yotta Acquisition's average media sentiment score of 0.00 beat Rain Oncology's score of -0.29 indicating that Yotta Acquisition is being referred to more favorably in the media. Company Overall Sentiment Yotta Acquisition Neutral Rain Oncology Neutral Does the MarketBeat Community favor YOTA or RAIN? Rain Oncology received 26 more outperform votes than Yotta Acquisition when rated by MarketBeat users. CompanyUnderperformOutperformYotta AcquisitionN/AN/ARain OncologyOutperform Votes2652.00% Underperform Votes2448.00% Do insiders & institutionals believe in YOTA or RAIN? 16.1% of Yotta Acquisition shares are held by institutional investors. Comparatively, 25.8% of Rain Oncology shares are held by institutional investors. 81.6% of Yotta Acquisition shares are held by company insiders. Comparatively, 17.4% of Rain Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is YOTA or RAIN more profitable? Company Net Margins Return on Equity Return on Assets Yotta AcquisitionN/A N/A N/A Rain Oncology N/A N/A -9.51% SummaryYotta Acquisition beats Rain Oncology on 4 of the 6 factors compared between the two stocks. Remove Ads Get Rain Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for RAIN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RAIN vs. The Competition Export to ExcelMetricRain OncologyHolding Offices IndustryBusiness SectorNASDAQ ExchangeMarket Cap$11.36M$445.32M$7.00B$7.50BDividend YieldN/A7.61%2.53%4.05%P/E RatioN/A2.1329.2018.08Price / SalesN/A50.31156.6789.38Price / Cash7.4169.0131.4034.64Price / Book-2.973.444.583.99Net Income$3.10M$35.22M$193.26M$247.18M Rain Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RAINRain OncologyN/A$2.05+6.2%N/AN/A$11.36MN/A0.0063Gap UpYOTAYotta AcquisitionN/A$11.38+0.0%N/A+8.0%$41.89MN/A0.00N/APositive NewsWAVSWestern Acquisition VenturesN/A$12.00-33.3%N/A+12.4%$40.80MN/A0.00N/ANews CoverageGap DownSHMDSCHMID GroupN/A$3.96+10.6%N/AN/A$40.10M$79.49M0.00800Short Interest ↓GDSTGoldenstone AcquisitionN/A$11.57flatN/AN/A$39.82MN/A0.00N/APositive NewsAOGOArogo Capital AcquisitionN/A$12.62flatN/A+11.0%$38.86MN/A0.00N/AGap DownELPWElong PowerN/A$0.74+26.5%N/AN/A$37.08M$1.40M0.00N/AGap UpINTEIntegral Acquisition Co. 1N/A$11.00flatN/AN/A$35.62MN/A0.002DISTDistoken AcquisitionN/A$11.04-0.6%N/A+4.9%$35.33MN/A0.00N/APositive NewsMCAEMountain Crest Acquisition Corp. IIIN/AN/AN/AN/A$35.04MN/A0.002,021BRACBroad Capital AcquisitionN/A$11.70flatN/AN/A$34.98MN/A0.002 Remove Ads Related Companies and Tools Related Companies Yotta Acquisition Competitors Western Acquisition Ventures Competitors SCHMID Group Competitors Goldenstone Acquisition Competitors Arogo Capital Acquisition Competitors Elong Power Competitors Integral Acquisition Co. 1 Competitors Distoken Acquisition Competitors Mountain Crest Acquisition Corp. III Competitors Broad Capital Acquisition Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RAIN) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rain Oncology Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rain Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
